Welcome to Natpar.com

This site is only for prescribing physicians outside the USA or UK who treat patients with hypoparathyroidism

Search Menu

Legal notice

Thank you for your interest in this part of the website of Takeda Pharmaceutical Company Ltd. (“Takeda”).

IMPORTANT: Please read this notice carefully – it applies to all persons who view the site and, depending on who you are and where you live, it may affect your rights. You should read it in full each time you visit the site. Viewing parts of the site may not be lawful in certain jurisdictions.

Takeda is pleased to provide HCPs outside the US and UK treating patients with hyperparathyroidism with this website and its content for general informational purposes. Please carefully read these terms and conditions relating to the use of our website. Takeda will use its best efforts to ensure that the information is accurate at the time it is added to the website.
Please note, however, that Takeda cannot guarantee that the information is accurate and accepts no liability for any losses or damage that may arise from relying on this information. The information may be changed by Takeda at any time, without notice to you. By using this website, you agree to these terms and conditions without limitation or qualification.

Use of materials and intellectual property rights
The copyright in this website belongs to Takeda. All other intellectual property rights are reserved. Takeda authorizes you to copy materials published on this website for non-commercial use only, provided that any copy of these materials which you make retains all copyright and other proprietary notices.

Links to third party websites
The website may from time to time contain hypertext-links to third parties’ websites. Takeda is not responsible for, and accepts no liability in respect of, any information or opinion contained on any other such site. As Takeda has no control over such sites and because their content is subject to change without notice to Takeda it is the responsibility of the user of the site to ensure that any information accessed is accurate and that software which is downloaded from that site is free of viruses or any other items of a destructive nature. Takeda and its subsidiaries accept no liability whatsoever in respect of any loss, damage, costs or liability incurred through any such downloaded material.

No Representation or Warranty
Takeda is not responsible for computer damage resulting from using the website. Takeda makes no representation or warranty that access to the website will be available on a timely basis, will be uninterrupted, or will be error-free. Takeda does not warrant that these pages, or the server that makes them available, are free of viruses or other harmful elements. In no event shall Takeda, its affiliates and subsidiaries, and their respective officers, directors, employees, agents, representatives, information providers, and licensors and their respective heirs and assigns, be liable for any direct, indirect, incidental, consequential, exemplary, special, punitive, or other damages even if informed of the possibility of such damages. The above exclusion may not apply in jurisdictions to the extent that they do not allow the exclusion of implied warranties.

Any personally identifiable information in electronic communications to this website is governed by Takeda’s privacy policy.

Natpar® (parathyroid hormone (rDNA)

Detailed Safety Information

Please consult the Natpar Summary Product Characteristics (SmPC) before prescribing.

Natpar treatment should be supervised by a physician or other qualified healthcare professional experienced in the management of patients with hypoparathyroidism. The goal of treatment is to achieve calcaemic control and to reduce symptoms. The optimisation of parameters of calcium phosphate metabolism should be in line with current therapeutic guidelines for the treatment of hypoparathyroidism. Prior to initiating and during treatment with Natpar confirm that 25-OH vitamin D stores are sufficient and that serum magnesium is within the reference range.


Natpar is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients, who are receiving or who have previously received radiation therapy to the skeleton, with skeletal malignancies or bone metastases, who are at increased baseline risk for osteosarcoma, with unexplained elevations of bone-specific alkaline phosphatase, with pseudohypoparathyroidism.

Warnings and Precautions

Monitoring of patients during treatment: pre-dose and in some cases post-dose serum calcium levels must be monitored during treatment with Natpar.

Hypercalcaemia: this was reported in clinical trials with Natpar. Hypercalcaemia commonly occurred during the titration period, during which doses of oral calcium, active vitamin D, and Natpar were being adjusted. Hypercalcaemia may be minimized by following the recommended dosing, the monitoring information and asking patients about any symptoms of hypercalcaemia. If severe hypercalcaemia develops, hydration and temporarily stopping Natpar, calcium and active vitamin D should be considered until serum calcium returns to the normal range. Then consider resuming Natpar, calcium and active vitamin D at lower doses.

Hypocalcaemia: a common clinical manifestation of hypoparathyroidism was reported in clinical trials with Natpar. Most of the hypocalcaemic events occurring in the clinical trials were mild to moderate severity. The risk for serious hypocalcaemia was greatest after the withdrawal of Natpar. Temporary or permanent discontinuation of Natpar must be accompanied by monitoring of serum calcium levels and increase of exogenous calcium and/or vitamin D sources as necessary. Hypocalcaemia may be minimized by following the recommended dosing, the monitoring information, and asking patients about any symptoms of hypocalcaemia.

Concomitant use with cardiac glycosides: Hypercalcaemia of any cause may predispose to digitalis toxicity, monitor serum calcium and cardiac glycoside levels and patients for signs and symptoms of digitalis toxicity.

Severe renal or hepatic disease: Natpar should be used with caution in patients with severe renal or hepatic disease because they have not been evaluated in clinical trials.

Use in young adults: Natpar should be used with caution in young adult patients with open epiphyses.

Tachyphylaxis: the calcium-raising effect of Natpar may diminish over time in some patients. The response of serum calcium concentration to administration of Natpar should be monitored at intervals to detect this and the diagnosis of tachyphylaxis considered.

Urolithiasis: Natpar has not been studied in patients with urolithiasis. Natpar should be used with caution in patients with active or recent urolithiasis because of the potential to exacerbate this condition.

Adverse Reactions

The most commonly observed adverse events with Natpar treatment were hypercalcaemia, hypocalcaemia, headache, diarrhoea, vomiting, paraesthesia, hypoaesthesia and hypercalciuria.

Very common

(frequency ≥1/10):

Hypercalcaemia, hypocalcaemia, headache, hypoaesthesia, paraesthesia, diarrhoea, nausea, vomiting, arthralgia, and muscle spasms.

(≥1/100 to <1/10):

Hypomagnesaemia, tetany, anxiety, insomnia, somnolence, palpitations, hypertension, cough, upper abdominal pain, muscle twitching, musculoskeletal pain, myalgia, neck pain, pain in extremities, hypercalciuria, pollakiuria, asthenia, chest pain, fatigue, injection site reactions, thirst, anti-PTH antibody positive, blood 25-hydroxycholecalciferol decreased, vitamin D decreased.



Material code: pi-00658
Date of Preparation of SI: February 2019

Prescribing Information

Body weight (kg) Volume to be injected (mL)
38–41 0.xx
42–45 0.xx
46–49 0.xx
50–53 0.xx
54–57 0.xx
58–61 0.xx
62–65 0.xx
66–69 0.xx
70–73 0.xx
74–77 0.xx
78–81 0.xx
82–85 0.xx
86–89 0.xx
90–93 0.xx

Shire group websites use cookies to maintain an optimal browsing experience. By continuing to view this website, you consent to our use of cookies. Information about our use of cookies is set out below.
Cookies are small text files that a website may place on your computer or mobile device when you visit a site or page. Cookies are useful because they allow the website to recognize your device the next time you visit.

How do Shire websites use cookies?
The cookies we use perform three different functions:

  1. Strictly necessary cookies
    We refer to some cookies as ‘strictly necessary’ cookies because they are essential to enable our visitors to use certain features on our websites. For example, if you enter a username or password to access a secure section of our website, a cookie may be set to keep you from having to enter these details more than once. These cookies do not record personal information that identifies you and are automatically deleted when you close your browser.
  2. Performance cookies
    These cookies are used to analyse how visitors use our website and to monitor our website’s performance. For example, we may check which pages get the most visits and the average time spent on our website. We use this information to improve how our website works. These cookies do not record personal information that identifies you: the information that we receive from them is in the form of aggregated statistics.
    These cookies are stored on your device even when you close your browser but can be deleted as described in the paragraph ‘How can I control or delete cookies?’ below.
  3. Functionality cookies
    These cookies allow our website to provide a more personal experience and remember any choices you may make. For example, if you visit our website using a mobile device but choose to access our main (non-mobile) site, a cookie may be set to prevent you from being re-directed to our mobile site. These cookies do not record personal information that identifies you. These cookies may be stored on your device even when you close your browser but can be deleted as described in the paragraph ‘How can I control or delete cookies?’ below.

How can I control or delete cookies?
Most browsers are initially set up to automatically accept cookies. You can change the settings on your browser to block cookies or to alert you when cookies are being set on your device. You can also delete cookies stored on your device through your browser. Please refer to your browser instructions or Help screen to learn more about how to adjust or modify your browser settings.
Please note that parts of our websites may not function correctly if you disable the cookies.